Figure 2. Nintedanib inhibits human Tenon’s fibroblast (HTF) proliferation and motility induced by transforming growth factor β1 (TGF-β1). A: HTFs were treated with TGF-β1 (5 ng/ml) in the presence or absence of different concentrations of nintedanib (0.1 μM, 0.5 μM, 1 μM) for 24 h. Cell proliferation was determined by cell counting kit-8 (CCK-8) assay. B: HTFs were treated with TGF-β1 (5 ng/ml) in the presence or absence of different concentrations of nintedanib (0.1 μM, 0.5 μM, 1 μM) for 24 h. Cell proliferation was determined by a 5-Bromo-2-deoxyUridine (BrdU) incorporation assay. C: HTFs were stimulated with TGF-β1 (5 ng/ml) for 24 h in the presence or absence of nintedanib (1 μM). Cell migration was evaluated by wound healing assay. Data are presented as the means ± standard deviations (SDs; n = 3) of independent repeated experiments (* p<0.01; ** p<0.01; *** p<0.001; **** p<0.0001 compared with control or TGF-β1 group).